WEBULL
WebtradeDownload

Should Bedside Tech Rollout Require Action From Zebra Stock Investors?

Simply Wall St · 2d ago
  • University Health recently announced it has rolled out Zebra Technologies’ TC5, HC2X/HC5X mobile computers and ZQ600 Plus printers across more than 90% of its inpatient frontline staff to support bedside scanning, medication verification and on-demand label printing integrated with the hospital’s electronic health record system.
  • The deployment turns Zebra devices into a data capture backbone for future AI at the bedside, where clean, real time clinical inputs trigger automated EHR alerts and support safer neonatal feeding, higher medication verification rates and faster wound documentation.
  • Next, the focus shifts to how this large scale healthcare rollout and its pipeline for future AI workflows might influence Zebra Technologies’ overall investment narrative.

Scan beyond Zebra Technologies and explore other hospital digitization opportunities by reviewing our hand picked 37 robotics and automation stocks that are wiring frontline care for automation, data capture and AI ready workflows.

Zebra Technologies Investment Narrative Recap

For Zebra Technologies, the simple belief is that critical workflows keep moving to mobile, data rich devices at the edge. The University Health rollout backs that up. It shows hospitals using Zebra hardware as the plumbing for automation and AI ready records rather than just barcode scanners and printers. The key near term swing factor still sits with how quickly large customers refresh gear and add software and services on top. The biggest risk remains that hardware heavy revenue and tariff exposure keep margins sensitive. This news helps the story but does not erase that dependence.

The University Health announcement is the clearest recent proof point that matters for this catalyst story. It puts Zebra hardware and services into a complex, regulated setting, where uptime, reliability and integration with an electronic health record are non negotiable. That kind of deployment can support the push toward more software, workflow tools and potentially higher margin services tied to a growing installed base. It also highlights operational pressure points. Large, bespoke rollouts require capital, strong support teams and clean execution across geographies that already show softness, which keeps execution risk front and center.

Even so, there is a less comfortable wrinkle in the Zebra Technologies story that only really shows up once you look at ...

Read the full Zebra Technologies narrative to see the case behind these numbers.

Zebra Technologies' narrative projects US$7.2b revenue and US$991.3m earnings by 2029. That pathway assumes 7.0% yearly revenue growth and requires an earnings increase of about US$452.3m from the current US$539.0m level.

Zebra Technologies' forecasts estimates fair value at $399.00 compared with $344.83, representing a 16% potential upside to its current price that could diminish quickly.

NasdaqGS:ZBRA 1-Year Stock Price Chart
NasdaqGS:ZBRA 1-Year Stock Price Chart

Exploring Other Perspectives

For Zebra Technologies, the alternate narrative leans into healthcare AI as a major catalyst. The most optimistic analysts were already modeling about US$7.3b revenue and US$1.1b earnings by 2029 before this University Health rollout and the upcoming Citi TMT appearance. You can treat those forecasts as one end of a wide range and explore how expectations might shift from here.

To stress test your own view on Zebra Technologies, compare it with the 4 other fair value estimates for Zebra Technologies from the wider community.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Looking For More Investment Ideas Beyond Zebra Technologies?

Once you have a view on Zebra Technologies, it can help to compare it with other businesses that fit different risk and quality profiles using the Simply Wall St Screener.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.